Cargando…

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis

MicroRNAs regulate bone homeostasis, and circulating microRNAs have been proposed as novel bone biomarkers. The effect of anti‐osteoporotic treatment on circulating microRNAs has not been described in detail. Therefore, we performed a comprehensive analysis of microRNA serum levels in ovariectomized...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weigl, Moritz, Kocijan, Roland, Ferguson, James, Leinfellner, Gabriele, Heimel, Patrick, Feichtinger, Xaver, Pietschmann, Peter, Grillari, Johannes, Zwerina, Jochen, Redl, Heinz, Hackl, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252367/ https://www.ncbi.nlm.nih.gov/pubmed/33598975 http://dx.doi.org/10.1002/jbmr.4276

Ejemplares similares

Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis—the MiDeTe study
por: Messner, Zora, et al.
Publicado: (2022)

Diagnostic Performance of a Panel of miRNAs (OsteomiR) for Osteoporosis in a Cohort of Postmenopausal Women
por: Kerschan-Schindl, K., et al.
Publicado: (2021)

Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry
por: Feichtinger, Xaver, et al.
Publicado: (2018)

Lugol’s solution but not formaldehyde affects bone microstructure and bone mineral density parameters at the insertion site of the rotator cuff in rats
por: Feichtinger, Xaver, et al.
Publicado: (2021)

Improved biomechanics in experimental chronic rotator cuff repair after shockwaves is not reflected by bone microarchitecture
por: Feichtinger, Xaver, et al.
Publicado: (2022)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single
por: Shin, Chang Jin, et al.
Publicado: (2016)

SVF-derived extracellular vesicles carry characteristic miRNAs in lipedema
por: Priglinger, Eleni, et al.
Publicado: (2020)

Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic
por: Kocijan, Roland, et al.
Publicado: (2021)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
por: Ohtori, Seiji, et al.
Publicado: (2017)

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
por: Taheri, Saeed, et al.
Publicado: (2019)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020)

Secretion of microvesicular miRNAs in cellular and organismal aging
por: Weilner, Sylvia, et al.
Publicado: (2013)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Effect of teriparatide on quality of life in patients with postmenopausal osteoporosis: a retrospective cohort study
por: Yang, Tiansong, et al.
Publicado: (2019)

Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters
por: Sandeep, Nandipati Venkata, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study
por: Ljunggren, Östen, et al.
Publicado: (2013)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Vertebral Collapse Prevented Following Teriparatide Treatment in Postmenopausal Kümmell's Disease Patients with Severe Osteoporosis
por: Gou, Peng‐guo, et al.
Publicado: (2021)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6cjkm3nj5vjktr83nma9d2jt8c